Global Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Metastatic Hepatocellular Carcinoma (HCC) Overview
3. Therapeutics Development
4. Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview
5. Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis
6. Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies
7. Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes
8. Metastatic Hepatocellular Carcinoma (HCC) Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies
13. Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes
14. Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development

• Acceleron Pharma, Inc.
• AstraZeneca Plc
• AVEO Pharmaceuticals, Inc.
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• HanAll Biopharma Co., Ltd.
• Incuron, LLC
• Johnson & Johnson
• Mirna Therapeutics, Inc.
• Molecular Partners AG
• MolMed S.p.A.
• Novartis AG
• OncoMed Pharmaceuticals, Inc.
• Pfizer Inc.
• PharmAbcine, Inc.
• Verlyx Pharma Inc.

For more information visit http://www.researchandmarkets.com/research/hr48dm/metastatic